Veritas Intercontinental opens an office in Bogota from which it will manage operations and commercial activity for Colombia and Latin America.
Veritas reinforces its commitment in the Latin American market with an approach to preventive medicine in which the analysis and interpretation of the genome offers a new perspective, enabling integral health care.
Veritas made the test available to anyone committed to taking care of their health and obtaining a better quality of life. The information received in the test result gives you an insight into the personal risks for developing more than 650 diseases, your carrier status, the pharmacogenomic profile and much more. For Veritas, genome sequencing is the first step in a journey that will change people’s lives.
Javier de Echevarría with Sebastián Robledo at the inauguration of the new office
Javier de Echevarría, CEO of Veritas Intercontinental, visited the team in Colombia. Sebastián Robledo, Regional Director Latin America, will be monitoring the strategy and activities along with the support of Ángela Gómez, Office & Project Manager.
The strategic location of the Veritas site next to the Country Clinic, a Colombian reference in precision and personalized medicine, strengthens the company’s objective of taking on the Latin American adventure in the hands of the most prestigious and innovative centers in the sector.
Veritas Intercontinental is the international subsidiary of Veritas Genetics, The Genome Company, which operates in Europe, Latin America, Japan and the Emirates. Its mission is to promote Whole Genome Sequencing and offer people information that empowers them to maximize the quality and duration of their lives and that of their families, changing the way in which the world conceives genetics.
Veritas was the first company to offer sequencing and interpretation of the whole genome to consumers and their physicians and leads the field of genetics, expanding the limits of science and technology and reducing the cost of the genome.
Veritas was founded in 2014 by leaders in genomics at Harvard Medical School and operates worldwide from its offices in the United States and Europe. The company has been recognized by MIT Technology Review as one of 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the most innovative healthcare companies in the world in 2018, and by CNBC as one of the companies Disruptor 50 companies in 2018 and 2019.